NVCR
NovoCure Limited
NASDAQ · JEHealthcareMedical - Instruments & Supplies
$15.94+0.13%
Price as of Jul 20, 2026
NVCR financials
NovoCure Limited financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $655.4M | $605.2M | $509.3M | $537.8M |
| Cost of revenue | $166.9M | $137.2M | $128.3M | $114.9M |
| Gross profit | $488.5M | $468.0M | $381.1M | $423.0M |
| Operating expenses | $642.3M | $638.5M | $614.7M | $512.5M |
| Operating income | -$153.8M | -$170.5M | -$232.9M | -$89.5M |
| Net income | -$136.2M | -$168.6M | -$207.0M | -$92.5M |
| EBITDA | -$119.0M | -$109.6M | -$177.5M | -$67.9M |
| Basic EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 |
| Diluted EPS | $-1.22 | $-1.56 | $-1.95 | $-0.88 |
| Balance sheet | ||||
| Cash & equivalents | $103.4M | $163.8M | $240.8M | $115.3M |
| Total assets | $804.3M | $1.2B | $1.1B | $1.2B |
| Total liabilities | $463.9M | $880.6M | $783.6M | $750.5M |
| Stockholders’ equity | $340.5M | $360.2M | $362.5M | $441.2M |
| Total debt | $290.0M | $683.4M | $596.2M | $584.3M |
| Net debt | $186.6M | $519.6M | $355.4M | $468.9M |
| Cash flow | ||||
| Operating cash flow | -$49.0M | -$26.4M | -$73.3M | $30.8M |
| Capital expenditure | -$26.6M | -$42.9M | -$27.1M | -$21.4M |
| Free cash flow | -$75.7M | -$69.2M | -$100.4M | $9.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |